Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06643377 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT06643377 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 27 participants.
The verdict
NCT06643377, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate will be called "enlicitide" from this point forward, The purpose of this study is to learn what happens to enlicitide in a person's body over time (a pharmacokinetic (PK) study). Researchers will compare what happens to enlicitide in the body when it is given to people with severe renal impairment (meaning the kidneys do not work properly) and to people who are in good health. The researchers believe that the total amount of enlicitide in a person's body measured during the 24 hours after a dose will be similar in people with severe renal impairment and in healthy people.
Interventions
- DRUG Enlicitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2024-11-22 |
| Est. Completion | 2025-06-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06643377
The ClinicalTrials.gov registry entry for NCT06643377 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enlicitide is the first listed.
NCT06643377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06643377 about?
NCT06643377 is a clinical study titled "A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)". Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate will be called "enlicitide" from this point forward, The purpose of this study is to learn what happens...
What is the current status of trial NCT06643377?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2024-11-22. Estimated completion is 2025-06-25.
What interventions are being tested in trial NCT06643377?
The interventions under investigation include: Enlicitide (DRUG).
Who is sponsoring clinical trial NCT06643377?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.